Omega-3 fatty acids and neurodegenerative diseases: New evidence in clinical trials

143Citations
Citations of this article
367Readers
Mendeley users who have this article in their library.

Abstract

A nutritional approach could be a promising strategy to prevent or slow the progression of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, since there is no effective therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established by a plethora of studies through their involvement in multiple biochemical functions, including synthesis of anti-inflammatory mediators, cell membrane fluidity, intracellular signaling, and gene expression. This systematic review will consider epidemiological studies and clinical trials that assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Indeed, treatment with omega-3 fatty acids, being safe and well tolerated, represents a valuable and biologically plausible tool in the management of neurodegenerative diseases in their early stages.

Cite

CITATION STYLE

APA

Avallone, R., Vitale, G., & Bertolotti, M. (2019, September 1). Omega-3 fatty acids and neurodegenerative diseases: New evidence in clinical trials. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms20174256

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free